Aprea Therapeutics is a clinical-stage biopharmaceutical company. Co.'s primary synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DNA damage response (DDR). Co. is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Co.'s primary WEE1 inhibitor product candidate is ATRN-1051. In addition, Co. has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. Finally, Co. also has an early preclinical research program, which is aimed at identification of inhibitors of a distinct protein involved in DDR. The APRE stock yearly return is shown above.
The yearly return on the APRE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the APRE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|